News
VANI
0.9834
-12.97%
-0.1466
Vivani Medical Reports Positive Phase 1 Results For Semaglutide Implant NPM-139; Stock Down
NASDAQ · 8h ago
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
Benzinga · 9h ago
Vivani Medical Reports SLIM-1 Phase 1 Trial Results
TipRanks · 11h ago
Vivani's Q3 Loss Widens Mildly To $7 Mln; Data For GLP-1 Implant Expected Later This Week
NASDAQ · 16h ago
Vivani Medical Q3 EPS $(0.08), Inline
Benzinga · 1d ago
Vivani Medical GAAP EPS of -$0.08 beats by $0.01
Seeking Alpha · 1d ago
*Vivani Medical 3Q Loss/Shr 8c >VANI
Dow Jones · 1d ago
Vivani Medical: Q3 Earnings Snapshot
Barchart · 1d ago
Weekly Report: what happened at VANI last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at VANI last week (1026-1030)?
Weekly Report · 11/02 09:04
Vivani Medical Updates on Cortigent–ClearOne Merger Timeline
TipRanks · 10/30 21:23
Vivani Medical Updates Investor Presentation and Disclosure Practices
TipRanks · 10/29 11:58
Weekly Report: what happened at VANI last week (1019-1023)?
Weekly Report · 10/26 09:04
Weekly Report: what happened at VANI last week (1012-1016)?
Weekly Report · 10/19 09:04
Weekly Report: what happened at VANI last week (1005-1009)?
Weekly Report · 10/12 09:04
Weekly Report: what happened at VANI last week (0928-1002)?
Weekly Report · 10/05 09:04
Weekly Report: what happened at VANI last week (0921-0925)?
Weekly Report · 09/28 09:04
Weekly Report: what happened at VANI last week (0914-0918)?
Weekly Report · 09/21 09:04
Vivani Medical Announces Merger Deal Involving Cortigent
TipRanks · 09/16 20:54
Weekly Report: what happened at VANI last week (0907-0911)?
Weekly Report · 09/14 09:04
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its segments include the Biopharm Division and Neurostimulation Division. Its pipeline includes NPM-139, NPM-133, NPM-115 and OKV-119. NPM-139 is a six-month, semaglutide implant under development for the treatment of chronic weight management. NPM-115 is an exenatide-based implant candidate also under development for the treatment of chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed for once or twice-yearly administration of medication.